(01 Oct 2024, 12:26)

Zydus' transdermal patch manufacturing facility completes USFDA inspection

Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

Zydus Lifesciences has received the EIR report from the USFDA for the inspection conducted at its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. This facility underwent an inspection from 15 to 19 July 2024 and has been classified as Voluntary Action Indicated (VAI).

More News

(04-Oct-2024 09:02)
Board of Cyient DLM approves acquisition of Altek Electronics Inc.
(04-Oct-2024 09:07)
Akzo Nobel NV undertakes strategic review of its portfolio
(04-Oct-2024 09:18)
GRSE signs contract for delivery of 5th multi-purpose vessel of 7,500 Dwt
(04-Oct-2024 09:29)
PNGS Gargi Fashion Jewellery schedules board meeting

More Company News View Company Information

Hot Pursuit (01-Oct-2024 12:13)
Zydus Life’s Ahmedabad facility gets EIR from USFDA
Corporate News (01-Oct-2024 12:26)
Zydus' transdermal patch manufacturing facility completes USFDA inspection
Corporate News (28-Sep-2024 14:21)
Zydus receives USFDA approval for Enzalutamide capsules
Hot Pursuit (28-Sep-2024 14:42)
Zydus Life gets final approval from USFDA for cancer drug
Hot Pursuit (19-Sep-2024 13:35)
Zydus Lifesciences Ltd drops for fifth straight session
Corporate News (17-Sep-2024 12:04)
Zydus Board approves business transfer agreement for acquisition of API biz of Sterling Biotech
Corporate News (13-Sep-2024 21:09)
Zydus enters into exclusive licensing and supply agreement with Viwit

Corporate News

Zydus' transdermal patch manufacturing facility completes USFDA inspection